RA cohort I | RA cohort II | RA cohort III | ||||
Included patients, n | 20 822 | 2047 | 15 575 | |||
Women, n (%) | 15 343 | (73.7) | 1467 | (71.7) | 11 559 | (74.2) |
Seropositive RA, n (%) | 14 987 | (72.0) | 1402 | (68.5) | 11 158 | (71.6) |
Age, mean (SD), years | 59.3 | (14.0) | 54.9 | (12.9) | 61.2 | (13.7) |
Age categories, n (%) | ||||||
<40 years | 2179 | (10.5) | 323 | (15.8) | 1289 | (8.3) |
40–44 years | 1228 | (5.9) | 127 | (6.2) | 786 | (5.1) |
45–49 years | 1476 | (7.06) | 179 | (8.7) | 1132 | (7.3) |
50–54 years | 2036 | (9.8) | 231 | (11.3) | 1354 | (8.7) |
55–59 years | 2937 | (14.1) | 320 | (15.6) | 1797 | (11.5) |
60–64 years | 3410 | (16.2) | 400 | (19.5) | 2234 | (14.3) |
65–69 years | 2816 | (13.5) | 309 | (15.1) | 2676 | (17.2) |
70–74 years | 2121 | (10.2) | 118 | (5.8) | 1995 | (12.8) |
≥75 years | 2619 | (12.6) | 40 | (2.0) | 2312 | (14.8) |
Diabetes mellitus, n (%) | 1427 | (6.9) | 114 | (5.6) | 1322 | (8.5) |
Hypertension, n (%) | 7345 | (35.3) | 540 | (26.4) | 6329 | (40.6) |
Hyperlipidaemia, n (%) | 2179 | (10.5) | 177 | (8.7) | 2135 | (13.7) |
Statin use, n (%) | 2096 | (10.1) | 170 | (8.3) | 2010 | (12.9) |
Smokers, n (%) | N/A | 612 | (29.9) | 2516 | (16.2) | |
Glucocorticoid use, n (%) | 10 717 | (51.5) | 902 | (44.1) | 7330 | (47.1) |
Any csDMARD use, n (%) | 17 439 | (83.8) | 1782 | (87.1) | 12 429 | (79.8) |
Methotrexate use, n (%) | 15 252 | (73.3) | 1584 | (77.4) | 10 958 | (70.4) |
Any bDMARD use, n (%) | 7146 | (34.3) | 344 | (16.8) | 5571 | (35.8) |
Disease duration, mean (SD), years | 9.4 | (10.6) | 3.5 | (3.9) | 12.4 | (11.2) |
Disease duration >10 years, n (%) | 7608 | (36.5) | 169 | (8.3) | 7727 | (49.6) |
DAS28, mean (SD) | 3.9 | (1.6) | 3.9 | (1.7) | 3.2 | (1.4) |
DAS28 ≥3.2, n (%) | 13 199 | (63.4) | 1284 | (62.7) | 6902 | (44.3) |
Modified CDAI, mean (SD) | 16.6 | (12.9) | 17.1 | (13.5) | 11.2 | (10.3) |
Modified CDAI >10, n (%) | 12 742 | (61.2) | 1246 | (60.9) | 6506 | (41.8) |
HAQ, mean (SD) | 0.90 | (0.68) | 0.75 | (0.62) | 0.80 | (0.66) |
HAQ>0.5, n (%) | 13 495 | (64.8) | 1178 | (57.6) | 9041 | (58.1) |
bDMARD, biological disease modifying antirheumatic drug; CDAI, clinical disease activity index; csDMARD, conventional synthetic disease modifying antirheumatic drug; DAS28, disease activity score 28-joint count; HAQ, health assessment questionnaire; N/A, not available; RA, rheumatoid arthritis